ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2240

Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Abstract Number: 1765

Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Abstract Number: 0404

Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Abstract Number: 0109

Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome
Abstract Number: 0929

Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms
Abstract Number: 2302

Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 0744

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
Abstract Number: 1629

Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Abstract Number: 1507

Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Abstract Number: 2144

Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Abstract Number: 2161

Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501
Abstract Number: 1247

Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Abstract Number: 1110

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Abstract Number: 0535

Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
Abstract Number: 0080

Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].